Your browser doesn't support javascript.
loading
Floor and ceiling effects in the EORTC QLQ-C30 Physical Functioning Subscale among patients with advanced or metastatic breast cancer.
Murugappan, Meena N; King-Kallimanis, Bellinda L; Mangir, Christina; Howie, Lynn; Bhatnagar, Vishal; Beaver, Julia A; Basch, Ethan M; Henson, Sydney R; Kluetz, Paul G.
Afiliación
  • Murugappan MN; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
  • King-Kallimanis BL; Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, Maryland.
  • Mangir C; Association of Community Cancer Centers, Rockville, Maryland.
  • Howie L; Pardee Hospital, University of North Carolina Health, Hendersonville, North Carolina.
  • Bhatnagar V; Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, Maryland.
  • Beaver JA; Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, Maryland.
  • Basch EM; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
  • Henson SR; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
  • Kluetz PG; Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, Maryland.
Cancer ; 128(4): 808-818, 2022 02 15.
Article en En | MEDLINE | ID: mdl-34634139
ABSTRACT

BACKGROUND:

The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 Physical Functioning subscale is a widely used patient-reported outcome measure that quantifies cancer patients' physical functioning. Strong floor/ceiling effects can affect a scale's sensitivity to change. The aim of this study was to characterize floor/ceiling effects of the physical functioning domain in patients with advanced/metastatic breast cancer enrolled in commercial clinical trials and a community-based trial.

METHODS:

The clinical trial cohort comprised patients from 5 registrational trials submitted to the Food and Drug Administration for review (2010-2017). The community cohort comprised a subgroup of patients from the Alliance Patient Reported Outcomes to Enhance Cancer Treatment (PRO-TECT) trial. The distribution of patient responses to Physical Functioning items and the summed score were assessed at the baseline and 3-month follow-up for both cohorts. Descriptive statistics were used to determine floor/ceiling effects at the item and scale levels.

RESULTS:

The clinical trial cohort and the community cohort consisted of 2407 and 178 patients, respectively. Twenty-four percent or more of the respondents reported "not at all" for having trouble/needing help with each Physical Functioning item across both cohorts and measurement time points. Fourteen to twenty percent of the patients scored perfectly (100 of 100) on the Physical Functioning subscale summary measure (where higher scores indicated better physical functioning) across both cohorts and time points.

CONCLUSIONS:

Minor floor effects and notable ceiling effects were found at the item and scale levels of the Physical Functioning subscale, regardless of cohort, and this creates some uncertainty about its ability to detect changes in physical functioning among high-functioning patients. Investigators may consider adding additional high-functioning items from the EORTC's item library to more accurately describe the impact of anticancer treatment on patients' physical functioning.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Neoplasias de la Mama Tipo de estudio: Clinical_trials Límite: Female / Humans Idioma: En Revista: Cancer Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Neoplasias de la Mama Tipo de estudio: Clinical_trials Límite: Female / Humans Idioma: En Revista: Cancer Año: 2022 Tipo del documento: Article